PET scan study for metastatic triple negative breast cancer
Part of Cancer, Skin clinical trials.
This study tests a new PET scan tracer called [68Ga]Ga-PentixaFor to see if it can better detect breast cancer that has spread. You may benefit if you have triple negative breast cancer that has come back or spread, and you are looking for more precise imaging.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with triple negative breast cancer that has spread to other parts of the body or come back after initial treatment.
- You are at least 18 years old.
- Your cancer is estrogen receptor negative (<10%), progesterone receptor negative (<10%), and HER2 not overexpressed.
- You have at least one tumor that can be measured on a standard PET/CT scan.
- Your overall health is good enough to have an ECOG performance status of 0 or 1.
- You have adequate kidney, liver, and blood cell function based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of PET scan that may help doctors see small cell lung cancer more clearly. It could improve treatment planning by showing where cancer has spread.
This trial uses a special PET scan to see if PSMA, a protein on some cancer cells, can help detect triple-negative breast cancer that has spread to other parts of the body.
This trial uses a special PET scan (68Ga-FAPI-46) to see if it can predict how well chemotherapy plus immunotherapy (pembrolizumab) works in people with triple-negative breast cancer before surgery. It aims to help doctors understand if the treatment is effective earlier.
This trial tests a new PET scan that uses a special tracer to find breast cancer that has spread. The scan may help doctors better see where the cancer is and guide treatment.
This trial uses a special scan (PSMA-PET/CT) to see if your breast cancer makes a protein called PSMA. The results might help guide your future treatment.
This trial uses a special PET scan to see how well your breast cancer is responding to neoadjuvant therapy (treatment given before surgery). The goal is to help doctors personalize your care by checking if the cancer is shrinking.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.